Business
Notice of Results
Scancell Holdings plc will announce its interim financial results for the six months ended 31 October 2025 on Thursday, 29 January 2026, and will also provide a business update. The company, which develops active immunotherapies for cancer, will host a live webcast for analysts and investors at 14:00 GMT on the day of the results. This announcement is a notice of upcoming financial reporting and an investor presentation, with no specific financial figures for the interim period yet disclosed. Disclaimer*
About this update from Scancell Holdings Plc
[{"type":"text","content":"\n\n22 January 2026\n \nScancell Holdings plc\n(\"Scancell\" or the \"Company\")\n \nNotice of Interim Results and Investor Presentation\nScancell Holdings plc (AIM: SCLP), the developer of active immunotherapies to treat cancer, will announce its interim financial results for the six months ended 31 October 2025 and provide a business update on progress achieved post-period, on Thursday 29 January 2026.\nPhillip L'Huillier, Chief Executive Officer, and Sath Nirmalananthan, Chief Financial Officer, will host a live webcast for analysts and investors on the day of the results at 14:00 GMT.\n \nIf you would like to join the webcast, please follow this link:\n \nInterim Financial Results for the six months ending 31 October 2025 | SparkLive | LSEG\n \n \n\n\n\n\nFor further information, please contact:\n\n\n\n\n\n\n\nScancell Holdings plc\n\n\n+44 (0) 20 3709 5700\n\n\n\n\nPhillip L'Huillier, CEO\nDr Jean-Michel Cosséry, Non-Executive Chairman\n \n\n\n\n\n\n\n\nPanmure Liberum Limited (Nominated Advisor and Joint Broker)\n\n\n+44 (0) 20 7886 2500\n\n\n\n\nEmma Earl/ Will Goode, Mark Rogers (Corporate Finance)\n\n\n\n\n\n\n\nRupert Dearden (Corporate Broking)\n \n\n\n\n\n\n\n\nWG Partners LLP (Joint Broker)\n\n\n+44 (0) 20 3705 9330\n\n\n\n\nDavid Wilson, Claes Spang\n \n\n\n\n\n\n\n\nInvestor and media relations\n\n\n\n\n\n\n\nMary-Ann Chang\n\n\n+44 (0) 20 7483 284853\[email protected]\n \n\n\n\n\nScancell (LSE:SCLP; www.scancell.co.uk) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies designed to generate safe, potent and long-lasting tumour-specific immunity for a cancer-free future. The lead product, iSCIB1+, an Immunobody® active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma. The precise patient population that iSCIB1+, in combination with CPIs bring benefit has been identified - enabling a precision-biomarker led registrational development. The lead Moditope® peptide active immunotherapy, Modi-1, is being investigated in a Phase 2 study in a broad rang...